Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Funder: National Institutes of Health
AGENCY
National Institutes of Health
PROGRAM
Discretionary
AMOUNT
—
CLOSES
Nov 16, 2029
Description
The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.
Eligibility
County governments; Special district governments; Small businesses; Private institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); City or township governments; Native American tribal organizations (other than Federally recognized tribal governments); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Independent school districts; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Native American tribal governments (Federally recognized); Public and State controlled institutions of higher education
Contact
Additional details
- Department
- HHS-Nih11
- Funding instrument
- Cooperative Agreement
- Cost sharing required
- No
- Archived
- Jan 15, 2030
Opportunity number: PAR-28-042
Quote this number when you contact the agency or apply.